ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1921

Clinical Spectrum of VEXAS Syndrome in a Rheumatology Department

Herman Mann1, Blanka Stiburkova2, Katerina Pavelcova1, Monika Belickova3, Cyril Salek3, Jana Juhaszova1 and Jiri Vencovsky4, 1Institute of Rheumatology, Praha 2, Czech Republic, 2Institute of Rheumatology, Prague, Czech Republic, 3Institute of Hematology and Blood Transfusion, Praha 2, Czech Republic, 4Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic

Meeting: ACR Convergence 2023

Keywords: Autoinflammatory diseases, genetics, Miscellaneous Rheumatic and Inflammatory Diseases

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1913–1944) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: VEXAS (vacuoles, E1 activating enzyme, X-linked, auto-inflammatory, somatic) syndrome is a clinically serious and potentially fatal adult-onset disease caused by somatic mutations in the UBA1 (Ubiquitin-like modifier activating enzyme 1) gene in hematopoietic progenitor cells. VEXAS syndrome clinically presents with inflammatory and hematological symptoms in middle and older age, predominantly in males. Multisystem inflammation most commonly affects the skin, eyes, joints, blood vessels, cartilage, and lungs. Patients with VEXAS syndrome may meet diagnostic criteria for several rheumatic diseases and/or hematological disorders. Given its heterogeneous clinical manifestations a high degree of clinical suspicion is required for pursuing the diagnosis of VEXAS syndrome; therefore, clinicians must be aware of the clinical features of VEXAS syndrome. The purpose of this study is to describe a series of cases diagnosed in a rheumatology department.

Methods: Institute of Rheumatology is the largest tertiary academic center providing care for patients with all types of inflammatory rheumatic diseases in the Czech Republic. Patients with symptom onset at age ≥40 years with undiagnosed inflammatory conditions, chondritis, unclassified vasculitis, neutrophilic dermatosis and classifiable inflammatory rheumatic diseases, which were a) resistant to standard therapy, b) associated with hematologic disorders or c)associated with atypical inflammatory manifestations for given diagnosis were considered for UBA1 testing. Retrospective chart review was performed to obtain pertinent demographic information and clinical data for patients with detected UBA1 somatic mutations.

Results: We have tested 22 patients (17 males and 5 females) with suspicious clinical phenotype and were able to detect previously described somatic UBA1 mutations in five of them. One additional patient with clonal cytopenia and multi-organ inflammatory features (patient 4) harbored a previously undescribed UBA1 variant in exon 14, which proved pathogenic in enzymatic analyses (1). Clinical features of individual patients are summarized in Table 1. All patients were males with a median age at symptom onset 66.5 years (IQR 57, 73) and median duration of symptoms prior to VEXAS syndrome diagnosis 3 years (IQR 2, 5). All patients were treated for a presumptive rheumatologic diagnosis with glucocorticoids and three patients received various other immunosupressants prior to the diagnosis of VEXAS syndrome. Myelodysplastic syndrome was diagnosed based on bone marrow biopsy in three patients, two additional patients had macrocytic anemia. Notably no cytopenia and normal MCV were present in one patient with longstanding inflammatory symptoms.

Conclusion: VEXAS syndrome presents with heterogenous clinical manifestations and should be considered in rheumatology patients with corresponding inflammatory phenotype even in the absence of hematologic abnormalities. 1) Stiburkova B, et al.Novel Somatic UBA1 Variant in a Patient With VEXAS Syndrome. Arthritis Rheumatol. 2023 Feb 10. doi: 10.1002/art.42471. Epub ahead of print.

Supported by Ministry of Health of the Czech Republic, grant nr. NU23-10-00160

Supporting image 1

Table 1: Clinical characteristics of patients with VEXAS syndrome


Disclosures: H. Mann: None; B. Stiburkova: None; K. Pavelcova: None; M. Belickova: None; C. Salek: None; J. Juhaszova: None; J. Vencovsky: Argenx, 2, Eli Lilly, 6, Galapagos, 2, Horizon, 2, Merck, 2.

To cite this abstract in AMA style:

Mann H, Stiburkova B, Pavelcova K, Belickova M, Salek C, Juhaszova J, Vencovsky J. Clinical Spectrum of VEXAS Syndrome in a Rheumatology Department [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/clinical-spectrum-of-vexas-syndrome-in-a-rheumatology-department/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-spectrum-of-vexas-syndrome-in-a-rheumatology-department/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology